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A B S T R A C TObjectives: Heavy menstrual bleeding negatively impacts the health
and quality of life of about 18 million women in the United States.
Although some studies have established the clinical effectiveness of
heavy menstrual bleeding treatments, few have evaluated their
cost-effectiveness. Our objective was to evaluate the cost-
effectiveness of the levonorgestrel-releasing intrauterine system
(LNG-IUS) compared with other therapies for idiopathic heavy
menstrual bleeding. Methods: We developed a model comparing
the clinical and economic outcomes (from a US payer perspective)
of three broad initial treatment strategies over 5 years: LNG-IUS,
oral agents, or surgery. Up to three nonsurgical treatment lines,
followed by up to two surgical lines, were allowed; unintended
pregnancy was possible, and women could discontinue any time
during nonsurgical treatments. Menstrual blood loss of 80 ml or
more per cycle determined treatment failure. Results: Initiating
treatment with LNG-IUS resulted in the fewest hysterectomies (6
per 1000 women), the most quality-adjusted life-years (3.78), andsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.11.011
ganz@unitedbiosource.com.
ondence to: Michael Ganz, United BioSource Corpothe lowest costs ($1137) among all the nonsurgical strategies.
Initiating treatment with LNG-IUS was also less costly than
surgery, resulted in fewer hysterectomies (vs. 9 per 1000 for
ablation) but was associated with fewer quality-adjusted life-years
gained per patient (vs. 3.80 and 3.88 for ablation and hysterectomy,
respectively). Sensitivity analyses confirmed these results. Con-
clusions: LNG-IUS resulted in the lowest treatment costs and the
fewest number of hysterectomies performed over 5 years com-
pared with all other initial strategies and resulted in the most
quality-adjusted life-years gained among nonsurgical options.
Initial treatment with LNG-IUS is the least costly and most
effective option for women desiring to preserve their fertility.
Keywords: cost-effectiveness, heavy menstrual bleeding, levonorgestrel-
releasing intrauterine system, United States.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Heavy menstrual bleeding (HMB), also referred to as menorrha-
gia, is a disorder characterized by heavy menstrual flow of 80 ml
or more of blood loss per cycle that affects women of reproduc-
tive age [1]. HMB negatively impacts women’s quality of life and
work productivity by interfering with routine daily activities,
work, and social engagements, and affects up to approximately
18 million women in the United States [2]. HMB can be caused by
organic pathology (such as fibroids) or can occur without any
pathology, in which case it is referred to as idiopathic or
dysfunctional uterine bleeding [3,4]. This study focuses entirely
on idiopathic HMB and therefore uses the term HMB.
Treatment options for women suffering from HMB include
hormonal and nonhormonal medications, such as combined oral
contraceptives (COCs), oral progestins, tranexamic acid (TXA
[Lysteda]), nonsteroidal anti-inflammatory drugs, danazol, and
the levonorgestrel-releasing intrauterine system (LNG-IUS [Mir-
ena]), and surgical interventions such as endometrial ablationand hysterectomy. Nonsurgical treatment options are often used
as first-line treatments and may be preferred by women who do
not want to undergo a surgical treatment that will impair their
fertility. For women who have not responded to these nonsurgi-
cal treatment options or who have completed childbearing,
however, endometrial ablation and hysterectomy are used [5].
Although a number of trials have established the clinical
evidence for the use of these treatment options [6–10], economic
evidence is also needed to ensure efficient allocation of limited
health care resources. A few studies, from perspectives other
than the US health care payers, have investigated the cost-
effectiveness and cost-utility of these treatments for women
with HMB who also desire contraception [11–14]. Only one study,
by Blumenthal et al. [15], has examined the cost-effectiveness of
LNG-IUS, oral contraceptives, and surgical management of idio-
pathic HMB in the US population by considering three scenarios:
women who have previously responded to a 3-month trial of
COCs, women who did not respond to COCs, and women naive to
medical therapy. After 5 years of treatment, costs associated withSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ration, 430 Bedford Street, Lexington, MA 02420, USA.
F
t
t
t
t
W
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 2 5 – 3 3 3326LNG-IUS were lower than those associated with other treatments
in all scenarios; LNG-IUS was more effective among COC respon-
ders, but less effective among COC nonresponders and women
who were treatment-naive.
The Blumenthal et al. [15] study, however, did not include
surgery as a first-line treatment option, separately consider
branded and generic COCs, or report outcomes in terms of
quality-adjusted life-years (QALYs), making it difficult to evaluate
incremental costs per outcome as reported in the broader
literature. Our objective was, therefore, to evaluate (from a US
payer perspective) the cost-effectiveness of LNG-IUS compared
with surgical and nonsurgical treatments for women requiring
treatment for HMB but who also desire contraception.Methods
Model Description
We developed a probabilistic state-transition model that simu-
lated the costs and outcomes, from a US payer perspective, of
hypothetical women with HMB who also desired contraception.
To capture the complex nature of disease progression, variations
in treatment patterns, and the importance of treatment history,
we implemented a patient-level (microsimulation) approach
using Visual Basic for Applications in Microsoft Excel. Patients
started treatment in one of three broad initial treatment strate-
gies: LNG-IUS, oral treatments, or surgery. Oral treatments
included generic COCs, branded COCs, TXA, and oral progestins;
surgery included endometrial ablation and hysterectomy.
Because TXA does not have contraceptive properties, we
assumed that women using TXA were also using condoms forContraception Failure
• If contraception failure occurs, women stay in the unintende
• If HMB symptoms do not return after three cycles, women e
• If HMB symptoms return after three cycles, women will eith
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omen can die at any point in the model. HMB, heavy menstrucontraception. Consistent with the approved maximum duration
of LNG-IUS use in the United States, we tracked patients, in the
base case, for 5 years during which time they could have
initiated, switched, or discontinued treatments. We tracked
patients for 10 years in a sensitivity analysis; a longer time
horizon is unlikely to be applicable because many potential
influences on HMB can change over this duration such as contra-
ceptive needs and preferences, pregnancy and breast-feeding
(which will stop menstruation for some time, after which HMB
may or may not return), and transition to menopause.
In this model, women could have received up to three
nonsurgical lines of therapy and up to two surgical lines of
therapy (Fig. 1). Treatment response probabilities are discussed
below and presented in Table 1, and the probabilities of treatment
switching and of other subsequent events are presented in
Appendix Tables 1 to 3 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2012.11.011.
Women continued using their initial nonsurgical (i.e., LNG-IUS
or oral) therapy until their menstrual blood loss was 80 ml or
more per cycle (i.e., they no longer responded to their treatment),
they became pregnant (i.e., experienced contraceptive failure),
they discontinued for other reasons, or they died. Women who
were not responding to the therapy could have switched to
another nonsurgical line of therapy, had surgery, or discontinued
treatment.
Initial surgical options for HMB included endometrial ablation
and hysterectomy. Women who had an ablation, either as their
initial therapy or as a non–first-line therapy (i.e., they switched
from a previous nonsurgical line), could have stopped responding
but, by assumption, could not become pregnant or discontinue
for other reasons. Women who no longer responded could have
elected to either undergo a hysterectomy or not to receive furtherd pregnancy state for three cycles. 
xperience a permanent end of HMB symptoms.
er discontinue all treatments or go to next Tx line.
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al bleeding; Tx, treatment.
Table 1 – Clinical inputs (treatment success probabilities for each 3-mo cycle) used in the model.
Treatment and cycle(s) Treatment
success
(A)
Contraceptive failure
(used in model)y (B)
Treatment
discontinuation (used
in model)z (C)
Computed treatment
success (used in model)§
(D)
LNG-IUS
Cycle 1 (and cycles 3þ) 1.0000 0.0005 0.0260 0.9735
Cycle 2 0.8480 0.0005 0.0260 0.8480
Branded and generic COCs
Cycle 1 0.5789 0.0206 0.0260 0.5789
Cycles 2þ 1.0000 0.0206 0.0260 0.9536
Oral progestin
Cycle 1 0.1181 0.0398 0.0260 0.1181
Cycles 2þ 1.0000 0.0398 0.0260 0.9342
Tranexamic acid (TXA)
Cycle 1 0.4190 0.0398 0.0260 0.4190
Cycles 2þ 1.0000 0.0398 0.0260 0.9342
Endometrial ablation
Cycle 1 (and cycles 13þ) 1.0000 0.0000 0.0000 1.0000
Cycle 2 0.8905 0.0000 0.0000 0.8905
Cycles 3 and 4 0.9713 0.0000 0.0000 0.9713
Cycles 5–12 0.9740 0.0000 0.0000 0.9740
COCs, combined oral contraceptives; LNG-IUS, levonorgestrel-releasing intrauterine system.
* Treatment success probabilities come from Kaunitz et al. [6] for LNG-IUS (cycle 2) and oral progestin (cycle 1), Berlex [7] and Endrikat et al. [8]
for COCs (cycle 1), Lukes et al. [9] for TXA (cycle 1), Bongers et al. [10] for ablation (cycle 2), and Garside et al. [16] for ablation (cycles 3, 4, and
5–12) . Probabilities for remaining treatments/cycles are by assumption.
y Annual contraceptive failure probabilities for LNG-IUS and COCs come from Trussell et al. [17] and were converted into 3-mo cycle
probabilities: 1(1annual probability)0.25. Contraceptive failure probabilities for oral progestin and TXA were set to that of condoms. The
probabilities are 0 for ablation by assumption.
z Three-month probabilities for discontinuation because of reasons other than contraceptive failure for LNG-IUS and COCs were derived from
the annual failure probability (10%) assumed in Blumenthal et al. [15] and are assumed to be the same for oral progestin and TXA and 0 for
ablation.
§ Computed probabilities of treatment success used in the model are calculated as D ¼ 1(B þ C) if 1ABCo0; otherwise as D ¼ A.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 2 5 – 3 3 3 327treatment (i.e., women could have no more than one ablation in
this model). We assumed that women who had a hysterectomy,
either as their initial therapy or as a non–first-line therapy,
immediately and permanently experienced an end to their HMB
symptoms and could not become pregnant.
Women who discontinued treatment remained in the model,
experienced a return of their HMB symptoms, and accrued costs
and outcomes associated with untreated HMB. Women who
became pregnant remained in the model, stopped experiencing
HMB symptoms, and accrued outcomes associated with the
contraceptive failure health state for three model cycles (9
months). We assumed that women experienced an end to their
HMB symptoms if their symptoms did not return after three
model cycles, in which case they entered the ‘‘cured after
pregnancy’’ health state for the remainder of the model simula-
tion. We further assumed that women transitioned to the next
available line of therapy (or discontinued treatment) if their
symptoms returned.
Because we wanted to be able to simulate the experience of
patients who would be eligible to receive any of the long-term
HMB treatments being evaluated, we assumed that women were
30 years old when they initiated treatment in this model. Thirty
years is approximately equal to the midpoint of the commonly
used definition of childbearing ages (15–44 years); in clinical
practice, younger women would be less likely to undergo surgical
treatments impacting future fertility. Although we did not con-
sider discontinuation due to potentially critical clinical condi-
tions (such as venous and arterial thromboembolic disorders,
cancer, and other serious adverse events) because of their very
low frequency, the model did include deaths related to back-
ground all-cause mortality.Costs and outcomes were assigned on the basis of a woman’s
clinical status (health state) at the end of each 3-month model
cycle. All costs and outcomes were summed at the end of the
model simulation to generate estimates of overall costs and
outcomes for each initial treatment strategy. All future costs
and QALYs were adjusted by using a 3% per-annum discount rate.
Data Sources
Clinical Inputs
The model required three categories of clinical input parameters:
treatment response (including contraceptive failure and discon-
tinuation for other reasons), treatment switching and choice of
treatments in subsequent lines of therapy, and mortality.
Data for treatment response came from recent clinical trial
publications and systematic literature reviews that assessed the
ability of the target treatments to reduce menstrual blood loss to
less than 80 ml per menstrual cycle and are shown in Table 1
[6–10,16]. The data presented in these studies came from samples
of women who shared similar observable baseline characteris-
tics. Their average ages ranged from 38 to 43 years and menstrual
blood loss ranged from 148 to 172 ml among studies that
objectively measured blood loss (studies that used a self-
assessed pictorial blood assessment chart [PBAC] reported typical
scores that ranged from 228 to 515). We used published prob-
abilities of treatment success for all oral treatments in the first
cycle that women started using those treatments [6–9]. We
further assumed that the probabilities of treatment success for
subsequent cycles were equal to 1BC, where B is the prob-
ability of contraceptive failure and C is the probability of dis-
continuing for other reasons. The probability of contraceptive
Table 2 – Economic inputs used in the model.
Health care resource Unit cost ($) Number of units used per cycle upon initiating relevant
treatment
During first cycle During subsequent cycles
LNG-IUS (one-time only)
Devicey 652.35 1.00 NA
Insertionz 103.46 1.00 NA
Removalz 115.65 1.00 NA
Drugs, per treatment cycle
Average of branded COCsz 147.71 1.00 1.00
Average of generic COCsz 69.18 1.00 1.00
Oral progestinz 2.97 1.00 1.00
TXAy 354.89 1.00 1.00
Surgery (one-time only, includes cost of one-time follow-up visit)z
Ablation 1361.82§
Hysterectomy 6180.81§
Cost of office visitz
LNG-IUS 47.89 1.00 0.25
Branded COCs 25.87 1.00 0.50
Generic COCs 25.87 1.00 0.50
Oral progestin 25.87 1.00 0.50
TXA 25.87 1.00 0.50
Ablation—One-time preoperative visit 120.53 1.00 0.00§
Hysterectomy—One-time preoperative visit 115.46 1.00 0.00§
Other costs
Untreated HMBz 25.87 1.00 1.00
COCs, combined oral contraceptives; HMB, heavy menstrual bleeding; LNG-IUS, levonorgestrel-releasing intrauterine system; NA, not
available/applicable; TXA, tranexamic acid.
* The number of units used during subsequent cycles might be less than 1.00 because they represent the average number of units per cycle
based on the assumed annual number of units used.
y Analysis of PriceRx database [23].
z Analysis of MarketScan database [20].
§ The costs of subsequent office visits are included in the base cost of the surgical procedure.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 2 5 – 3 3 3328failure came from Trussell et al. [17], and the 3-month probability
of discontinuing for other reasons was derived from the annual
failure probability assumed by Blumenthal et al. [15]. Because the
number of bleeding and spotting days may not start to decrease
until after 3 to 6 months after being fitted with the LNG-IUS [18],
we assumed that response to HMB treatment was evaluated after
6 months; hence, we assumed that the probability of treatment
success for the first cycle was equal to 1BC and the published
probability of treatment success was applied at cycle 2. Women
using LNG-IUS faced a 5% probability of experiencing placement
failure during the model cycle in which it was inserted (the
probability of placement failure is assumed to be negligible in
other model cycles), which can happen in any treatment line [19].
We also assumed that ablation was fully effective at stopping
HMB symptoms during the first cycle (published probabilities of
treatment success were used for subsequent cycles [10,16]) and
that hysterectomy was fully effective at stopping HMB symptoms
during all cycles. We assumed zero probabilities of contraceptive
failure and discontinuing for other reasons for both ablation and
hysterectomy.
The probabilities of treatment switching and the choice of
treatments in subsequent lines of therapy (presented in Appen-
dix Tables 1–3 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2012.11.011) were derived in part from an analy
sis of the Thomson Medstat MarketScan Commercial Claims
database (Thomson Reuters Healthcare, Inc., Ann Arbor, MI,
USA) [20], results of which were previously reported [21], and
on the basis of our assumptions. MarketScan is a nationallyrepresentative medical claims database representing approxi
mately 50 million employees and their spouses and dependents
who were covered by approximately 100 different insurance
companies, Blue Cross-Blue Shield plans, and third-party admin
istrators, living in all 10 US census regions.
Age-specific female all-cause mortality rates were obtained
from US life tables from the National Vital Statistics Reports
produced by the Centers for Disease Control and Prevention [22].Economic Inputs
Patients incurred the cost of the relevant therapy and associated
office visits during each model cycle for all nonsurgical treat-
ments. Patients undergoing treatment with LNG-IUS incurred the
cost of the device and its insertion in the first cycle of its use and
also incurred removal costs in the cycle in which patients
discontinued treatment. We assumed that patients incurred
one office visit in the cycle in which they initiated treatment
and that patients using LNG-IUS incurred one additional office
visit per year. Patients on all other nonsurgical treatments were
assumed to incur two additional visits per year. Patients under-
going surgery incurred the one-time cost of the surgery and one-
time follow-up office visit costs related to surgery. Physician and
surgery costs were obtained from the MarketScan database [20].
Drug and LNG-IUS costs were obtained from the Medi-Span Price
Rx database (Wolters Kluwer, Health, Indianapolis, IN, USA),
which contains current and full historical (for 35 years) pricing
data for more than 170,000 active and inactive drug products [23].
Table 3 – Health-related quality-of-life inputs.
Health state Utility
value
Utility inputs, nonsurgical treatments
Baseline 0.760
Contraceptive failure 0.840
Respond 0.840
Fail 0.760
Utility inputs, surgical treatments
Respond 0.840
Fail 0.760
Utility inputs, regardless of type of treatment
Return of HMB symptoms (due to treatment
discontinuation)
0.760
Cured after pregnancy 0.840
Death 0.000
Disutilities (for use in sensitivity analyses)
Surgical recuperation during first cycle following
ablationy
0.055
Surgical recuperation during first cycle following
hysterectomyy
0.067
Loss of fertility during all cycles following surgical
treatmentz
0.070
HMB, heavy menstrual bleeding.
* Utility values come from Hurskainen et al. [24].
y Disutility values derived from Roberts et al. [14].
z Disutility value comes from Scotland et al. [25].
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 2 5 – 3 3 3 329This model does not account for the costs associated with
pregnancy, births, abortions, or miscarriages because the current
focus is on the costs associated with HMB. All the economic
inputs used in the model are summarized in Table 2.
Health State Utilities
The utility values, which measure preferences for health states,
used in the model came from a Finnish study that elicited
utilities, using the EuroQol five-dimensional questionnaire
instrument, from 236 women who experienced menorrhagia
and were treated with either LNG-IUS or hysterectomy, which
is, to our knowledge, the most recent primary source of utility
data [24]. Because the baseline (untreated) and treated utility
values were not statistically different between the two treatment
groups, we used the values associated with LNG-IUS treatment inTable 4 – Five-year summary clinical and economic resu
Initial
treatment
strategy
Total QALYs
(per patient)
Total hysterectomies
(per 1000 patients)
LNG-IUS 3.78 6
Branded COCs 3.71 37
Generic COCs 3.71 37
Oral progestin 3.67 113
TXA 3.72 76
Ablation 3.79 9
Hysterectomy 3.88 1000
COC, combined oral contraceptive; LNG-IUS, levonorgestrel-releasin
tranexamic acid.
* Hysterectomies avoided are computed as 1000 minus the number of hysour model. We found no empirical support for disutility (reduc-
tion in utility) associated with side effects of different HMB
treatments and assumed that, in our base case, the health state
utilities in the model (Table 3) were independent of underlying
treatments and of line of therapy. We did not account for
disutility resulting from unintended pregnancy or loss of fertility
in the base case, because there is likely to be a large variation
across women with and without completed family planning. Two
of the potentially important impacts on utilities, the effects of
convalescence and of loss of fertility following surgery, are
addressed in sensitivity analyses.
Model Analyses
The model calculated the total costs and outcomes as the
relevant mean values across all women in each initial treatment
strategy cohort. We computed incremental cost-effectiveness
ratios (ICERs) using total costs, QALYs gained, and number of
hysterectomies avoided (¼1000 minus the number of hysterec-
tomies performed). The ICER is defined as the ratio of the cost
difference to the outcome difference for two competing therapies.
The ICER is a single metric that summarizes the value for money
of one intervention compared with another. Dominated therapies
(i.e., ones that were more expensive and less effective than other
therapies) were not considered when calculating ICERs.
The parameter values used in the model came from a variety
of sources and naturally may have varying levels of uncertainty.
To assess how sensitive the model results are to variations in
model inputs, we conducted multiple one-way sensitivity ana-
lyses that varied the time horizon and the discount rate, intro-
duced disutilities associated with recuperation and loss of
fertility following surgery [14,25], and gave women equal prob-
abilities of receiving each treatment in subsequent treatment
lines among those treatments they did not previously fail. We
also assessed the impact of changing all effectiveness probabil-
ities, all utilities, and all costs by25%. In addition, we conducted
probabilistic sensitivity analyses to assess the robustness of the
model results by accounting for simultaneous uncertainty in
model inputs. We performed five thousand Monte-Carlo simula-
tions during which we simultaneously varied the treatment
success probabilities, utilities, and drug costs by sampling these
parameters at random from their assumed distributions. We
sampled probabilities and utilities from beta distributions and
costs from gamma distributions. The means for these distribu-
tions were set equal to their base-case values and, because
appropriate variance data were not available in the sources for
these parameters, we approximated the SDs by 0.25m, where m islts for model base case.
Total hysterectomies avoided
(per 1000 patients)
Average total costs
(per patient) ($)
994 1137
963 1804
963 1196
887 1583
924 3065
991 2612
0 6250
g intrauterine system; QALY, quality-adjusted life-year; TXA,
terectomies (per 1000 patients) for a given initial treatment strategy.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 2 5 – 3 3 3330the base case (mean) of the parameter. The results of the
probabilistic sensitivity analysis are summarized and displayed
by using cost-effectiveness acceptability curves.Results
Women who initiated treatment with LNG-IUS gained more
(discounted) QALYs (3.8) and experienced fewer hysterectomies
(6 per 1000 women) over 5 years than did women who initiated
treatment with other nonsurgical strategies (approximately 3.7
QALYs on average and 37–113 hysterectomies per 1000 women).
Women who initiated treatment with ablation or hysterectomy
gained 3.8 to 3.9 QALYs, respectively (Table 4). Initial treatment
with LNG-IUS was associated with the lowest total costs ($1137)
among all initial treatment strategies, which ranged from $1196
for generic COCs to $6250 for hysterectomy (Table 4; see Appen-
dix Tables 4 and 5 for further results in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2012.11.011).
Overall, initiating treatment with LNG-IUS was associated
with lower costs and fewer hysterectomies than with all other
comparators (i.e., LNG-IUS dominated all comparators with
hysterectomies avoided as an outcome). Initiating treatment with
LNG-IUS also dominated all nonsurgical comparators when out-
comes were measured by using QALYs. Ablation and hysterect-
omy generated more QALYs at higher costs (the ICERs were
$49,614 per QALY for hysterectomy and $122,278 for ablation:
Fig. 2). Although the initial ablation strategy resulted in slightly
more QALYs gained than did the initial LNG-IUS strategy, LNG-
IUS dominated ablation through extended dominance (i.e., a
combination of LNG-IUS and hysterectomy could have produced
a scenario in which incremental costs were lower and incre-
mental QALYs gained were larger than for ablation).
Multiple one-way sensitivity analyses (Table 5; see Appendix
Table 6 in Supplemental Materials found at: http://dx.doi.org/10.
1016/j.jval.2012.11.011 for detailed results) demonstrated that, in
most cases, initiating treatment with LNG-IUS resulted in lower
costs and more QALYs gained than with other initial treatment
strategies, which suggested that the model results were not sensi
tive to variations in the discount rate, the distribution of treatment
options in subsequent treatment lines, or the time horizon (after 10
years, LNG-IUS still dominated all nonsurgical initial treatment
strategies; the ICERs for both ablation and hysterectomy compared(ICER = $122,278)
(ICER = $49,614)
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Fig. 2 – Cost-effectiveness frontier (costs per QALY). Ablation
resulted in higher QALYs and higher costs than did LNG-IUS
(ICER ¼ $122,278) but is dominated by the combination of
LNG-IUS and hysterectomy (extended dominance). COC,
combined oral contraceptive; ICER, incremental cost-
effectiveness ratio; LNG-IUS, levonorgestrel-releasing
intrauterine system; QALY, quality-adjusted life-year; TXA,
tranexamic acid.with that for LNG-IUS wereo$15,000 per additional QALY). LNG-IUS
dominated both ablation and hysterectomy if the disutilities for
recuperation following surgery and/or loss of fertility applied, except
for hysterectomy when only considering the disutility associated
with surgery (ICER was almost $59,000 per additional QALY).
Although our base-case conclusions were unchanged when we
varied all utilities and costs by25%, conclusions were more
sensitive to changes in the effectiveness probabilities.
LNG-IUS was the dominant strategy, in the probabilistic
sensitivity analyses, against all other treatments in at least 95%
of the simulations except generic COCs (dominant in 63%) and
ablation (dominant in 50%) when outcomes were measured by
hysterectomies avoided. When outcomes were measured by
QALYs, LNG-IUS was the dominant strategy in 49% (vs. generic
COCs) to 76% (vs. branded COCs) of the simulations compared
with nonsurgical treatments and dominant against ablation in
40% and against hysterectomy in 33% of the simulations. As the
cost-effectiveness acceptability curves show in Figure 3, initiating
treatment with LNG-IUS would be considered a cost-effective
(including dominant) strategy anywhere from 71% (vs. hysterect-
omy) to 96% (vs. oral progestin) of the time at a willingness-to-
pay level of $30,000 per QALY and anywhere from 88% (vs.
ablation and hysterectomy) to 97% (vs. oral progestin) of the time
at a willingness-to-pay level of $60,000 per QALY.Discussion
We evaluated the costs and outcomes of seven initial treatment
strategies for HMB for women who also desired contraception.
Our analyses showed that initiating treatment with LNG-IUS was
associated with lower costs and with more QALYs gained than
with other nonsurgical treatments. In addition to QALYs, we
evaluated the cost-effectiveness of these treatments using the
number of hysterectomies avoided. Based on this outcome, an
initial LNG-IUS treatment strategy was more effective and less
costly than all other initial treatment strategies except hyster-
ectomy. Although these results may be expected simply because
LNG-IUS and ablation exhibit the highest treatment success
probabilities and the lowest contraceptive failure probabilities
of the treatments evaluated here, this model explicitly accounts for
the outcomes of subsequent therapies along the treatment
pathways.
Our findings are consistent with the few published studies
that have assessed the cost-effectiveness of nonsurgical treat-
ments for women with HMB. Blumenthal et al. [15] reported that
LNG-IUS was the most cost-effective treatment strategy, when
assessed using bleeding treatment and contraceptive success, for
managing dysfunctional uterine bleeding from a US perspective
among women who previously responded to oral contraceptive
therapy (it should be noted, however, that this model grouped
branded and generic COCs together and used outdated costs).
Our results are also consistent with findings from studies con-
ducted in Hong Kong [11], Spain [13], and the United Kingdom
[12,14] that showed that LNG-IUS was more cost-effective than
oral treatments and, in most cases, ablation, as well as with a
recent literature review on the cost-effectiveness and quality
of life associated with the use of LNG-IUS as a treatment for
HMB [26].
Because published data were not always available for all
aspects of the model, we needed to make a number of simplify-
ing assumptions, which may limit the robustness and general-
izability of our results. Because there were no data available for
success probabilities that were fully conditional on a woman’s
treatment history, we had to assume that the probabilities of
treatment success were independent of the treatment(s) a
woman previously used and that the probability of treatment
Table 5 – One-way sensitivity analysis results: Incremental cost-effectiveness ratios, LNG-IUS vs. comparators.
Scenario Branded
COCs
Generic COCs Oral progestin TXA Ablation ($) Hysterectomy
($)
Quality-adjusted life-years
Discount rate (%)
0 LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
154,600 46,655
6 LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
163,000 50,930
Disutilities
Due to surgery LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
LNG-IUS
dominates
58,904
Due to loss of fertility LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
LNG-IUS
dominates
LNG-IUS
dominates
Due to surgery þ loss of
fertility
LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
LNG-IUS
dominates
LNG-IUS
dominates
Time horizon (y)
2 LNG-IUS
dominates
Generic COCs less costly,
less effective
LNG-IUS dominates LNG-IUS
dominates
96,100 130,850
10 LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
13,951 14,506
Equal pathway probabilities LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
65,833 53,222
All effectiveness parameters
Decreased by 25% LNG-IUS
dominates
Generic COCs less costly,
less effective
Oral progestin less costly,
less effective
LNG-IUS
dominates
LNG-IUS
dominates
31,220
Increased by 25% LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
22,672 63,703
All utilities
Decreased by 25% LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
163,038 66,152
Increased by 25% LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
781,488 87,019
All costs
Decreased by 25% LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
91,706 37,210
Increased by 25% LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
152,851 62,020
Hysterectomies avoided (per 1,000 patients)
Discount rate (%)
0 LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
LNG-IUS
dominates
6 LNG-IUS
dominates
LNG-IUS dominates LNG-IUS dominates LNG-IUS
dominates
LNG-IUS
dominates
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 2 5 – 3 3 3332success was independent of the line of treatment. Our results
should be reevaluated if the required probability data become
available. Because of paucity of empirical data relevant for the
HMB population in the United States, we did not explicitly
account for disutility due to side effects potentially associated
with any treatment. Furthermore, because long-term data were
unavailable, we assumed that the conditional probabilities of
treatment success for all nonsurgical treatments beyond cycle 1
(cycle 2 for LNG-IUS) were 1.00 (before adjustment for contra-
ceptive failure and discontinuation for other reasons). The
effectiveness data used for these treatment success probabilities
were taken directly from the relevant treatment arms of clinical
trials reported in the literature, which may have introduced
confounding due to differences in patient characteristics or
methods among studies. Finally, because the data sources that
provided the treatment success probabilities [6–10,16] did not
report information on the proportion of patients who became
pregnant, we obtained these data from other sources. Combining
data from different sources, including different underlying
patient samples, further introduces uncertainty to the model
and its results.
Despite an in-depth literature search, we were able to
retrieve only one source of utilities associated with HMB and
its treatment [24]. On the basis of the data in that study, which
showed no differences between treatment with LNG-IUS or
hysterectomy, we assumed that the utility of response was
independent of treatment and applied the utility associated
with successful treatment with LNG-IUS to all successful
treatments, which may not be valid. Using Finnish utilities
for a US study, although not optimal, is unlikely to critically
challenge the validity of the model and its results as would, for
example, using non-US cost or treatment pattern data. Our
analysis also assumes that the utility of contraceptive failure
(pregnancy) is the same as that for treatment success because
women who are pregnant no longer experience HMB symp-
toms. Some readers may challenge this assumption, because
women who sought contraceptive treatment but became preg-
nant can be expected to have experienced some disutility.
However, this decision stemmed from the lack of data avail-
able in the literature regarding the disutility of pregnancy in
HMB population. Furthermore, although we expected the
utility of treatment success associated with surgical and
nonsurgical treatment options to differ because of recupera-
tion and potential adverse events of surgery, we were unable to
locate actual data to support this assumption. Hence, we used
the same utility values, and as a result, we may have over-
estimated the utility associated with ablation and hysterect-
omy. But as our sensitivity analyses have shown, an initial
LNG-IUS strategy can cost less and provide better outcomes
after accounting for plausible disutilities associated with
surgical treatments.Conclusions
Over a 5-year period, compared with other initial treatment
strategies, LNG-IUS resulted in lower treatment costs and the
fewest hysterectomies performed. LNG-IUS also resulted in the
most QALYs gained among nonsurgical options, but fewer QALYs
than hysterectomy (under certain plausible assumptions about
the disutilities associated with surgical treatments, LNG-IUS can
result in more QALYs gained than hysterectomy). Hence, for
women who would like to preserve their fertility, initial treat-
ment with LNG-IUS is the least costly and most effective treat-
ment option. These results support the use of LNG-IUS as the
first-line HMB treatment option.
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